Evelo Biosciences Announces Proposed Public Offering of Common Stock
Evelo Biosciences, Inc. (Nasdaq: EVLO) announced a public offering of $50 million in common stock, with a potential additional $7.5 million for over-allotments. Proceeds will fund the development of EDP1815 for psoriasis and atopic dermatitis trials, alongside other clinical studies and R&D efforts. Morgan Stanley, Cowen, and BMO Capital Markets are managing the offering. While the registration statement has been declared effective, actual completion and terms remain uncertain. Risks include fluctuations in stock price and market conditions.
- Intended use of funds for advancing clinical trials of EDP1815 in psoriasis and atopic dermatitis.
- Plans to progress additional candidates, including EDP1867 and EDP2939, through various clinical phases.
- Possible dilution of shares due to the public offering.
- No assurance of the offering's completion or actual terms.
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it intends to offer and sell, subject to market and other conditions,
Morgan Stanley, Cowen and BMO Capital Markets are acting as joint book-running managers for the offering.
Evelo intends to use the net proceeds from the offering, in addition to its existing cash resources, for the following purposes: (i) continue the development of EDP1815 in a Phase 2 trial in psoriasis and initiate a Phase 2 trial of EDP1815 in atopic dermatitis; (ii) prepare to advance EDP1815 in multiple Phase 3 trials in psoriasis and atopic dermatitis, upon receipt of positive Phase 2 data; (iii) continue the Phase 2 and Phase 2/3 clinical trials of EDP1815 for the treatment of hyperinflammation caused by SARs-CoV-2; (iv) advance EDP1867 in a Phase 1b trial in atopic dermatitis; (v) progress its first bacterial extracellular vesicle product candidates into the clinic, including EDP2939 for inflammation and EDP1908 for oncology; (vi) other research and development activities for additional product candidates, including advancing additional oral product candidates through preclinical development across therapeutic areas; and (vii) the remainder, if any, for working capital and other general corporate purposes.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. The securities will be offered only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated use of proceeds of the proposed offering. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in Evelo’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as the other factors discussed in the “Risk Factors” section in the registration statement referenced above and in Evelo’s most recently filed Quarterly Report on Form 10-Q, as well as other risks detailed in Evelo’s filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. There can be no assurance that Evelo will be able to complete the proposed public offering on the anticipated terms. All information in this press release is as of the date of the release, and Evelo undertakes no duty to update this information, even if subsequent events cause its views to change, unless required by law.
| Contact: |
| Evelo Biosciences |
| Jessica Cotrone 978-760-5622 jcotrone@evelobio.com |
FAQ
What is Evelo Biosciences' recent stock offering?
How will Evelo use the proceeds from the stock offering?
Who is managing the public offering for EVLO?
What risks are associated with Evelo's stock offering?
